U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H22FN5O3
Molecular Weight 423.4402
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SPEBRUTINIB

SMILES

COCCOC1=CC=C(NC2=NC=C(F)C(NC3=CC(NC(=O)C=C)=CC=C3)=N2)C=C1

InChI

InChIKey=KXBDTLQSDKGAEB-UHFFFAOYSA-N
InChI=1S/C22H22FN5O3/c1-3-20(29)25-16-5-4-6-17(13-16)26-21-19(23)14-24-22(28-21)27-15-7-9-18(10-8-15)31-12-11-30-2/h3-10,13-14H,1,11-12H2,2H3,(H,25,29)(H2,24,26,27,28)

HIDE SMILES / InChI

Molecular Formula C22H22FN5O3
Molecular Weight 423.4402
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Spebrutinib (CC-292, AVL-292) is a selective inhibitor of BTK that was under clinical development for the treatment of rheumatoid arthritis (phase II) and B-cell Lymphoma (phase I). The drug was discovered by Avila Therapeutics, but then acquired by Celgene. Spebrutinib covalently binds to Cys 481 in BTK, blocking the ATP-binding pocket of the enzyme. The drug is no longer in Celgene's pipeline and its development is supposed to be terminated.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
5.9 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.
2016 Jul
Patents

Sample Use Guides

Patients should take oral spebrutinib in a dose of 375 mg daily (250 mg in the AM and 125 mg in the PM for 28 days).
Route of Administration: Oral
Cells from the Ramos lymphoma cell line, which expresses an intact BCR signaling pathway, were treated with increasing concentrations of spebrutinib for 1 hour and lysed, and the percent occupancy of BTK was determined with ELISA. The concentration of spebrutinib required for 50% occupancy was 5.9 nM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:23:16 UTC 2023
Edited
by admin
on Fri Dec 15 18:23:16 UTC 2023
Record UNII
DRU6NG543J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SPEBRUTINIB
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
3-(5-FLUORO-2-(4-(2-METHOXYETHOXY)PHENYLAMINO)PYRIMIDIN-4-YLAMINO)PHENYL)ACRYLAMIDE
Systematic Name English
CC-292
Code English
AVL-292
Code English
SPEBRUTINIB [USAN]
Common Name English
Spebrutinib [WHO-DD]
Common Name English
N-(3-((5-FLUORO-2-((4-(2-METHOXYETHOXY)PHENYL)AMINO)PYRIMIDIN-4-YL)AMINO)PHENYL)ACRYLAMIDE
Systematic Name English
spebrutinib [INN]
Common Name English
BTK INHIBITOR CC-292
Common Name English
2-PROPENAMIDE, N-(3-((5-FLUORO-2-((4-(2-METHOXYETHOXY)PHENYL)AMINO)-4-PYRIMIDINYL)AMINO)PHENYL)-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C124801
Created by admin on Fri Dec 15 18:23:16 UTC 2023 , Edited by admin on Fri Dec 15 18:23:16 UTC 2023
NCI_THESAURUS C129825
Created by admin on Fri Dec 15 18:23:16 UTC 2023 , Edited by admin on Fri Dec 15 18:23:16 UTC 2023
FDA ORPHAN DRUG 408313
Created by admin on Fri Dec 15 18:23:16 UTC 2023 , Edited by admin on Fri Dec 15 18:23:16 UTC 2023
Code System Code Type Description
DRUG BANK
DB11764
Created by admin on Fri Dec 15 18:23:16 UTC 2023 , Edited by admin on Fri Dec 15 18:23:16 UTC 2023
PRIMARY
SMS_ID
100000169951
Created by admin on Fri Dec 15 18:23:16 UTC 2023 , Edited by admin on Fri Dec 15 18:23:16 UTC 2023
PRIMARY
NCI_THESAURUS
C97037
Created by admin on Fri Dec 15 18:23:16 UTC 2023 , Edited by admin on Fri Dec 15 18:23:16 UTC 2023
PRIMARY
EVMPD
SUB183689
Created by admin on Fri Dec 15 18:23:16 UTC 2023 , Edited by admin on Fri Dec 15 18:23:16 UTC 2023
PRIMARY
ChEMBL
CHEMBL3301625
Created by admin on Fri Dec 15 18:23:16 UTC 2023 , Edited by admin on Fri Dec 15 18:23:16 UTC 2023
PRIMARY
EPA CompTox
DTXSID101026012
Created by admin on Fri Dec 15 18:23:16 UTC 2023 , Edited by admin on Fri Dec 15 18:23:16 UTC 2023
PRIMARY
INN
10004
Created by admin on Fri Dec 15 18:23:16 UTC 2023 , Edited by admin on Fri Dec 15 18:23:16 UTC 2023
PRIMARY
CAS
1202757-89-8
Created by admin on Fri Dec 15 18:23:16 UTC 2023 , Edited by admin on Fri Dec 15 18:23:16 UTC 2023
PRIMARY
USAN
AB-94
Created by admin on Fri Dec 15 18:23:16 UTC 2023 , Edited by admin on Fri Dec 15 18:23:16 UTC 2023
PRIMARY
FDA UNII
DRU6NG543J
Created by admin on Fri Dec 15 18:23:16 UTC 2023 , Edited by admin on Fri Dec 15 18:23:16 UTC 2023
PRIMARY
PUBCHEM
59174488
Created by admin on Fri Dec 15 18:23:16 UTC 2023 , Edited by admin on Fri Dec 15 18:23:16 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
IRREVERSIBLE INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY